{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:20:57Z","timestamp":1792686057213,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T00:00:00Z","timestamp":1473984000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s11154-016-9386-8","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T03:04:31Z","timestamp":1473995071000},"page":"571-581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Relapse prediction in Graves\u00b4 disease: Towards mathematical modeling of clinical, immune and genetic markers"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1155-7395","authenticated-orcid":false,"given":"Christoph","family":"Langenstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Schork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Badenhoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,16]]},"reference":[{"key":"9386_CR1","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1056\/NEJMcp0801880","volume":"358","author":"GA Brent","year":"2008","unstructured":"Brent GA. Clinical practice. Graves\u2019 disease. N Engl J Med. 2008;358:2594\u2013605.","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"9386_CR2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1055\/s-0029-1211712","volume":"104","author":"K Badenhoop","year":"1996","unstructured":"Badenhoop K, Donner H, Braun J, Siegmund T, Rau H, Usadel KH. Genetic markers in diagnosis and prediction of relapse in Graves\u2019 disease. Exp Clin Endocrinol Diabetes. 1996;104(Suppl):98\u2013100.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"9386_CR3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/dc08-2339","volume":"32","author":"P Gillard","year":"2009","unstructured":"Gillard P, Huurman V, Van der Auwera B, Decallonne B, Poppe K, Roep BO, et al. Graves hyperthyroidism after stopping immunosuppressive therapy in type 1 diabetic islet cell recipients with pretransplant TPO autoantibodies. Diabetes Care. 2009;32:1817\u20139.","journal-title":"Diabetes Care"},{"key":"9386_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12688","author":"L Bartalena","year":"2014","unstructured":"Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves\u2019 disease. Clin Endocrinol. 2014. doi: 10.1111\/cen.12688 .","journal-title":"Clin Endocrinol"},{"key":"9386_CR5","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra042972","volume":"352","author":"DS Cooper","year":"2005","unstructured":"Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352:905\u201317.","journal-title":"N Engl J Med"},{"key":"9386_CR6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/thy.1997.7.369","volume":"7","author":"P Vitti","year":"1997","unstructured":"Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, et al. Clinical features of patients with Graves\u2019 disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7:369\u201375.","journal-title":"Thyroid"},{"key":"9386_CR7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-2265.2005.02397.x","volume":"63","author":"M Ueda","year":"2005","unstructured":"Ueda M, Inaba M, Kumeda Y, Nagasaki T, Hiura Y, Tahara H, et al. The significance of thyroid blood flow at the inferior thyroid artery as a predictor for early Graves\u2019 disease relapse. Clin Endocrinol. 2005;63:657\u201362.","journal-title":"Clin Endocrinol"},{"key":"9386_CR8","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJM200010263431707","volume":"343","author":"AP Weetman","year":"2000","unstructured":"Weetman AP. Graves\u2019 disease. N Engl J Med. 2000;343:1236\u201348.","journal-title":"N Engl J Med"},{"key":"9386_CR9","first-page":"930","volume":"86","author":"TH Brix","year":"2001","unstructured":"Brix TH, Kyvik KO, Christensen K, Hegedus L. Evidence for a major role of heredity in Graves\u2019 disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab. 2001;86:930\u20134.","journal-title":"J Clin Endocrinol Metab"},{"key":"9386_CR10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/105072502760258613","volume":"12","author":"D Ringold","year":"2002","unstructured":"Ringold D. A, Nicoloff JT, Kesler M, Davis H, Hamilton a, Mack T: further evidence for a strong genetic influence on the development of autoimmune thyroid disease: the California twin study. Thyroid. 2002;12:647\u201353.","journal-title":"Thyroid"},{"key":"9386_CR11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jaut.2015.07.009","volume":"64","author":"HJ Lee","year":"2015","unstructured":"Lee HJ, Li CW, Hammerstad SS, Stefan M, Tomer Y. Immunogenetics of autoimmune thyroid diseases: a comprehensive review. J Autoimmun. 2015;64:82\u201390.","journal-title":"J Autoimmun"},{"key":"9386_CR12","doi-asserted-by":"crossref","first-page":"183.e1","DOI":"10.1016\/j.amjmed.2009.06.030","volume":"123","author":"K Boelaert","year":"2010","unstructured":"Boelaert K, Newby PR, Simmonds MJ, Holder RL, Carr-Smith JD, Heward JM, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010;123:183.e1\u20139.","journal-title":"Am J Med"},{"key":"9386_CR13","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1089\/105072502761016467","volume":"12","author":"J Orgiazzi","year":"2002","unstructured":"Orgiazzi J, Madec A-M. Reduction of the risk of relapse after withdrawal of medical therapy for Graves\u2019 disease. Thyroid. 2002;12:849\u201353.","journal-title":"Thyroid"},{"key":"9386_CR14","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1089\/thy.2007.0003","volume":"17","author":"T Tagami","year":"2007","unstructured":"Tagami T, Hagiwara H, Kimura T, Usui T, Shimatsu A, Naruse M. The incidence of gestational hyperthyroidism and postpartum thyroiditis in treated patients with Graves\u2019 disease. Thyroid. 2007;17:767\u201372.","journal-title":"Thyroid"},{"key":"9386_CR15","first-page":"4254","volume":"85","author":"V Jubault","year":"2000","unstructured":"Jubault V, Penfornis A, Schillo F, Hoen B, Izembart M, Timsit J, et al. Sequential occurrence of thyroid autoantibodies and Graves\u2019 disease after immune restoration in severely immunocompromised human immnunodeficiency virus-1-infected patients. J Clin Endocrinol Metab. 2000;85:4254\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"9386_CR16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000104859","volume":"13","author":"M Bagnasco","year":"2006","unstructured":"Bagnasco M, Bossert I, Pesce G. Stress and autoimmune thyroid diseases. Neuroimmunomodulation. 2006;13:309\u201317.","journal-title":"Neuroimmunomodulation"},{"key":"9386_CR17","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.3390\/nu7042485","volume":"7","author":"J Wang","year":"2015","unstructured":"Wang J, Lv S, Chen G, Gao C, He J, Zhong H, et al. Meta-analysis of the association between vitamin D and autoimmune thyroid disease. Nutrients. 2015;7:2485\u201398.","journal-title":"Nutrients"},{"key":"9386_CR18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2006-924256","volume":"114","author":"A Kurylowicz","year":"2006","unstructured":"Kurylowicz A, Ramos-Lopez E, Bednarczuk T, Badenhoop K. Vitamin D-binding protein (DBP) gene polymorphism is associated with Graves\u2019 disease and the vitamin D status in a polish population study. Exp Clin Endocrinol Diabetes. 2006;114:329\u201335.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"9386_CR19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1089\/105072502320288483","volume":"12","author":"D Corapcioglu","year":"2002","unstructured":"Corapcioglu D, Tonyukuk V, Kiyan M, Yilmaz AE, Emral R, Kamel N, et al. Relationship between thyroid autoimmunity and Yersinia enterocolitica antibodies. Thyroid. 2002;12:613\u20137.","journal-title":"Thyroid"},{"key":"9386_CR20","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3748\/wjg.v18.i10.1093","volume":"18","author":"V Bassi","year":"2012","unstructured":"Bassi V, Marino G, Iengo A, Fattoruso O, Santinelli C. Autoimmune thyroid diseases and helicobacter pylori: the correlation is present only in Graves\u2019s disease. World J Gastroenterol. 2012;18:1093\u20137.","journal-title":"World J Gastroenterol"},{"key":"9386_CR21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/thy.2006.16.563","volume":"16","author":"A Antonelli","year":"2006","unstructured":"Antonelli A, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Rotondi M, et al. Thyroid disorders in chronic hepatitis C virus infection. Thyroid. 2006;16:563\u201372.","journal-title":"Thyroid"},{"key":"9386_CR22","first-page":"788","volume":"15","author":"AP Weetman","year":"1994","unstructured":"Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev. 1994;15:788\u2013830.","journal-title":"Endocr Rev"},{"key":"9386_CR23","first-page":"146","volume":"12","author":"A Aleksi\u0107","year":"2009","unstructured":"Aleksi\u0107 A, Aleksi\u0107 Z, Stojanovi\u0107 M. TSH receptor antibodies for confirming the diagnosis and prediction of remission duration, in newly diagnosed Graves\u2019 disease patients. Hell J Nucl Med. 2009;12:146\u201350.","journal-title":"Hell J Nucl Med"},{"key":"9386_CR24","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2014.10.016","volume":"14","author":"A Antonelli","year":"2015","unstructured":"Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev. 2015;14:174\u201380.","journal-title":"Autoimmun Rev"},{"key":"9386_CR25","doi-asserted-by":"crossref","first-page":"E31","DOI":"10.25011\/cim.v38i1.22574","volume":"38","author":"H Yu","year":"2015","unstructured":"Yu H, Farahani P. Thyroid stimulating hormone suppression post-therapy in patients with Graves\u2019 disease: a systematic review of pathophysiology and clinical data. Clin Invest Med. 2015;38:E31\u201344.","journal-title":"Clin Invest Med"},{"key":"9386_CR26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1055\/s-0035-1555901","volume":"47","author":"S Neumann","year":"2015","unstructured":"Neumann S, Place RF, Krieger CC, Gershengorn MC. Future prospects for the treatment of Graves\u2019 hyperthyroidism and eye disease. Horm Metab Res. 2015;47:789\u201396.","journal-title":"Horm Metab Res"},{"key":"9386_CR27","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40618-014-0136-z","volume":"37","author":"M Marin\u00f2","year":"2014","unstructured":"Marin\u00f2 M, Latrofa F, Menconi F, Chiovato L, Vitti P. An update on the medical treatment of Graves\u2019 hyperthyroidism. J Endocrinol Investig. 2014;37:1041\u20138.","journal-title":"J Endocrinol Investig"},{"key":"9386_CR28","first-page":"312","volume":"73","author":"R Wilson","year":"1988","unstructured":"Wilson R, McKillop JH, Pearson C. Burnett a K, Thomson J a: differential immunosuppressive action of carbimazole and propylthiouracil. Clin Exp Immunol. 1988;73:312\u20135.","journal-title":"Clin Exp Immunol"},{"key":"9386_CR29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2174\/1381612013397898","volume":"7","author":"R Volp\u00e9","year":"2001","unstructured":"Volp\u00e9 R. The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Curr Pharm Des. 2001;7:451\u201360.","journal-title":"Curr Pharm Des"},{"key":"9386_CR30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cellimm.2015.02.002","volume":"294","author":"MR Gubbels Bupp","year":"2015","unstructured":"Gubbels Bupp MR. Sex, the aging immune system, and chronic disease. Cell Immunol. 2015;294:102\u201310.","journal-title":"Cell Immunol"},{"key":"9386_CR31","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nri803","volume":"2","author":"M Sopori","year":"2002","unstructured":"Sopori M. 21 review: effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002;2:372\u20137.","journal-title":"Nat Rev Immunol"},{"key":"9386_CR32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1530\/eje.0.1460153","volume":"146","author":"P Vestergaard","year":"2002","unstructured":"Vestergaard P. Smoking and thyroid disorders--a meta-analysis. Eur J Endocrinol. 2002;146:153\u201361.","journal-title":"Eur J Endocrinol"},{"key":"9386_CR33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-13-0811","volume":"170","author":"E Mohlin","year":"2014","unstructured":"Mohlin E, Filipsson Nystr\u00f6m H, Eliasson M. Long-term prognosis after medical treatment of Graves\u2019 disease in a northern Swedish population 2000-2010. Eur J Endocrinol. 2014;170:419\u201327.","journal-title":"Eur J Endocrinol"},{"key":"9386_CR34","doi-asserted-by":"crossref","first-page":"525936","DOI":"10.1155\/2012\/525936","volume":"2012","author":"C Kamath","year":"2012","unstructured":"Kamath C, Adlan MA, Premawardhana LD. The role of thyrotrophin receptor antibody assays in Graves\u2019 disease. J Thyroid Res. 2012;2012:525936.","journal-title":"J Thyroid Res"},{"key":"9386_CR35","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.crohns.2014.02.002","volume":"8","author":"GC Parkes","year":"2014","unstructured":"Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect. J Crohn\u2019s Colitis. 2014;8:717\u201325.","journal-title":"J Crohn\u2019s Colitis"},{"key":"9386_CR36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cccn.2004.08.020","volume":"352","author":"LN Guerra","year":"2005","unstructured":"Guerra LN, R\u00edos De Molina MDC, Miler EA, Moiguer S, Karner M, Burdman JA. Antioxidants and methimazole in the treatment of Graves\u2019 disease: effect on urinary malondialdehyde levels. Clin Chim Acta. 2005;352:115\u201320.","journal-title":"Clin Chim Acta"},{"key":"9386_CR37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/cen.12066","volume":"78","author":"A Drutel","year":"2013","unstructured":"Drutel A, Archambeaud F, Caron P. Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol. 2013;78:155\u201364.","journal-title":"Clin Endocrinol"},{"key":"9386_CR38","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1530\/eje.1.02210","volume":"155","author":"P Laurberg","year":"2006","unstructured":"Laurberg P, J\u00f8rgensen T, Perrild H, Ovesen L, Knudsen N, Pedersen IB, et al. The Danish investigation on iodine intake and thyroid disease, DanThyr: status and perspectives. Eur J Endocrinol. 2006;155:219\u201328.","journal-title":"Eur J Endocrinol"},{"key":"9386_CR39","first-page":"1","volume":"10","author":"XG Vos","year":"2016","unstructured":"Vos XG, Endert E, Zwinderman K, Tijssen JGP, Wiersinga WM. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves\u2019 hyperthyroidism. J Clin Endocrinol Metab. 2016;10:1\u201310.","journal-title":"J Clin Endocrinol Metab"},{"key":"9386_CR40","first-page":"427","volume":"49","author":"D Dauksiene","year":"2013","unstructured":"Dauksiene D, Dauksa A, Mickuviene N. Independent pretreatment predictors of Graves\u2019 disease outcome. Med. 2013;49:427\u201334.","journal-title":"Med"},{"key":"9386_CR41","first-page":"2986","volume":"81","author":"O T\u00f6rring","year":"1996","unstructured":"T\u00f6rring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, et al. Graves\u2019 hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid study group. J Clin Endocrinol Metab. 1996;81:2986\u201393.","journal-title":"J Clin Endocrinol Metab"},{"key":"9386_CR42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000342621","volume":"1","author":"P-W Wang","year":"2013","unstructured":"Wang P-W, Chen I-Y, Juo S-HH, Hsi E, Liu R-T, Hsieh C-J. Genotype and phenotype predictors of relapse of Graves\u2019 disease after antithyroid drug withdrawal. Eur Thyroid J. 2013;1:251\u20138.","journal-title":"Eur Thyroid J"},{"key":"9386_CR43","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02933.x","volume":"67","author":"AK Eckstein","year":"2007","unstructured":"Eckstein AK, Lax H, L\u00f6sch C, Glowacka D, Plicht M, Mann K, et al. Patients with severe Graves\u2019 ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol. 2007;67:607\u201312.","journal-title":"Clin Endocrinol"},{"key":"9386_CR44","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1530\/acta.0.1200689","volume":"120","author":"H Schleusener","year":"1989","unstructured":"Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, et al. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves\u2019 disease. Acta Endocrinol. 1989;120:689\u2013701.","journal-title":"Acta Endocrinol"},{"key":"9386_CR45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/thy.1998.8.119","volume":"8","author":"V Michelangeli","year":"1998","unstructured":"Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves\u2019 disease with antithyroid drugs. Thyroid. 1998;8:119\u201324.","journal-title":"Thyroid"},{"key":"9386_CR46","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1089\/105072502321085225","volume":"12","author":"R Hoermann","year":"2002","unstructured":"Hoermann R, Quadbeck B, Roggenbuck U, Szabolcs I, Pfeilschifter J, Meng W, et al. Relapse of Graves\u2019 disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine. Thyroid. 2002;12:1119\u201328.","journal-title":"Thyroid"},{"key":"9386_CR47","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1055\/s-0035-1559633","volume":"47","author":"SA Morshed","year":"2015","unstructured":"Morshed SA, Davies TF. Graves\u2019 disease mechanisms: the role of stimulating, blocking, and cleavage region TSH receptor antibodies. Horm Metab Res. 2015;47:727\u201334.","journal-title":"Horm Metab Res"},{"key":"9386_CR48","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1210\/jc.2012-4309","volume":"98","author":"G Barbesino","year":"2013","unstructured":"Barbesino G, Tomer Y. Clinical review: clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab. 2013;98:2247\u201355.","journal-title":"J Clin Endocrinol Metab"},{"key":"9386_CR49","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1172\/JCI26031","volume":"115","author":"TF Davies","year":"2005","unstructured":"Davies TF, Ando T, Lin R-Y, Tomer Y, Latif R. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest. 2005;115:1972\u201383.","journal-title":"J Clin Invest"},{"key":"9386_CR50","doi-asserted-by":"crossref","unstructured":"Liu X, Qiang W, Liu X, Liu L, Liu S, Gao A, et al.: A 6-year follow-up of a randomized prospective trial comparing methimazole treatment with or without exogenous L-thyroxine in Chinese patients with Graves \u2019 Disease 2014;564\u2013567.","DOI":"10.1055\/s-0034-1377045"},{"key":"9386_CR51","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12020-013-9895-0","volume":"44","author":"P Anagnostis","year":"2013","unstructured":"Anagnostis P, Adamidou F, Polyzos SA, Katergari S, Karathanasi E, Zouli C, et al. Predictors of long-term remission in patients with Graves\u2019 disease: a single center experience. Endocrine. 2013;44:448\u201353.","journal-title":"Endocrine"},{"key":"9386_CR52","first-page":"1","volume":"1","author":"P Abraham","year":"2010","unstructured":"Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism. Cochrane Database Syst Rev. 2010;1:1.","journal-title":"Cochrane Database Syst Rev"},{"key":"9386_CR53","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2265.1999.00629.x","volume":"50","author":"D Maugendre","year":"1999","unstructured":"Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, et al. Antithyroid drugs and Graves\u2019 disease--prospective randomized assessment of long-term treatment. Clin Endocrinol. 1999;50:127\u201332.","journal-title":"Clin Endocrinol"},{"key":"9386_CR54","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1365-2265.1998.00554.x","volume":"49","author":"G Benker","year":"1998","unstructured":"Benker G, Reinwein D, Kahaly G, Tegler L, Alexander WD, Fassbinder J, et al. Is there a methimazole dose effect on remission rate in Graves\u2019 disease? Results from a long-term prospective study. The European multicentre trial Group of the Treatment of hyperthyroidism with antithyroid drugs. Clin Endocrinol. 1998;49:451\u20137.","journal-title":"Clin Endocrinol"},{"key":"9386_CR55","first-page":"1516","volume":"76","author":"D Reinwein","year":"1993","unstructured":"Reinwein D, Benker G, Lazarus JH, Alexander WD. A prospective randomized trial of antithyroid drug dose in Graves\u2019 disease therapy. European multicenter study group on antithyroid drug treatment. J Clin Endocrinol Metab. 1993;76:1516\u201321.","journal-title":"J Clin Endocrinol Metab"},{"key":"9386_CR56","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/08916930701464897","volume":"40","author":"T Vang","year":"2007","unstructured":"Vang T, Miletic AV, Bottini N, Mustelin T. Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity. 2007;40:453\u201361.","journal-title":"Autoimmunity"},{"key":"9386_CR57","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12020-014-0289-8","volume":"48","author":"R Vita","year":"2015","unstructured":"Vita R, Lapa D, Trimarchi F, Benvenga S. Stress triggers the onset and the recurrences of hyperthyroidism in patients with Graves\u2019 disease. Endocrine. 2015;48:254\u201363.","journal-title":"Endocrine"},{"key":"9386_CR58","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1089\/thy.2004.14.1047","volume":"14","author":"T Mizokami","year":"2004","unstructured":"Mizokami T, Wu Li A, El-Kaissi S, Wall JR. Stress and thyroid autoimmunity. Thyroid. 2004;14:1047\u201355.","journal-title":"Thyroid"},{"key":"9386_CR59","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1089\/thy.1996.6.659","volume":"6","author":"S Benvenga","year":"1996","unstructured":"Benvenga S. Benzodiazepine and remission of Graves\u2019 disease. Thyroid. 1996;6:659\u201360.","journal-title":"Thyroid"},{"key":"9386_CR60","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ncpendmet1006","volume":"5","author":"R Vita","year":"2009","unstructured":"Vita R, Lapa D, Vita G, Trimarchi F, Benvenga S. A patient with stress-related onset and exacerbations of Graves disease. Nat Clin Pract Endocrinol Metab. 2009;5:55\u201361.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"9386_CR61","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1210\/jc.2008-0966","volume":"93","author":"M Rotondi","year":"2008","unstructured":"Rotondi M, Cappelli C, Pirali B, Pirola I, Magri F, Fonte R, et al. The effect of pregnancy on subsequent relapse from Graves\u2019 disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab. 2008;93:3985\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"9386_CR62","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1350-4533(02)00049-8","volume":"24","author":"SW Smye","year":"2002","unstructured":"Smye SW, Clayton RH. Mathematical modelling for the new millenium: medicine by numbers. Med Eng Phys. 2002;24:565\u201374.","journal-title":"Med Eng Phys"},{"key":"9386_CR63","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10928-014-9363-3","volume":"41","author":"L Canini","year":"2014","unstructured":"Canini L, Perelson AS. Viral kinetic modeling: state of the art. J Pharmacokinet Pharmacodyn. 2014;41:431\u201343.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9386_CR64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF02481809","volume":"16","author":"Danziger, Elmergreen","year":"1954","unstructured":"Danziger, Elmergreen. Mathematical Theory of Periodic Relapsing Catatonia. Bull Math Biophys. 1954;16:15\u201321.","journal-title":"Bull Math Biophys"},{"key":"9386_CR65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02477840","volume":"18","author":"Danziger, Elmergreen","year":"1956","unstructured":"Danziger, Elmergreen. The thyroid-pituitary homeostatic mechanism. Bull Math Biophys. 1956;18:1\u201313.","journal-title":"Bull Math Biophys"},{"key":"9386_CR66","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF02476688","volume":"30","author":"N Rashevsky","year":"1968","unstructured":"Rashevsky N. Mathematical theory of biological periodicities: formulation of the n-body case. Bull Math Biophys. 1968;30:735\u201349.","journal-title":"Bull Math Biophys"},{"key":"9386_CR67","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF02498768","volume":"27","author":"K Norwich","year":"1965","unstructured":"Norwich K, Raymond R. Homeostatic control of the thyroxin concentration expressed by a set of linear differential equations. Bull Math Biophys. 1965;27:133\u201344.","journal-title":"Bull Math Biophys"},{"key":"9386_CR68","first-page":"8","volume":"30","author":"J DiStefano","year":"1968","unstructured":"DiStefano J, Stear E. Neuroendocrine control of thyroid secretion in living systems: a feedback control system model. Bull Math Biophys. 1968;30:8\u201326.","journal-title":"Bull Math Biophys"},{"key":"9386_CR69","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF00336982","volume":"52","author":"T Hatakeyama","year":"1985","unstructured":"Hatakeyama T, Yagi H. Computer simulation for hormones related to primary Thyropathy. Biol Cybern. 1985;52:259\u201366.","journal-title":"Biol Cybern"},{"key":"9386_CR70","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0895-7177(94)90042-6","volume":"19","author":"Y Liu","year":"1994","unstructured":"Liu Y, Liu B, Xie J, Liu YX. A new mathematical model of hypothalamo-pituitary-thyroid axis. Math Comput Model. 1994;19:81\u201390.","journal-title":"Math Comput Model"},{"key":"9386_CR71","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.mbs.2007.10.009","volume":"212","author":"M Degon","year":"2008","unstructured":"Degon M, Chipkin SR, Hollot CV, Zoeller RT, Chait Y. A computational model of the human thyroid. Math Biosci. 2008;212:22\u201353.","journal-title":"Math Biosci"},{"key":"9386_CR72","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1530\/EJE-10-0106","volume":"162","author":"R Hoermann","year":"2010","unstructured":"Hoermann R, Eckl W, Hoermann C, Larisch R. Complex relationship between free thyroxine and TSH in the regulation of thyroid function. Eur J Endocrinol. 2010;162:1123\u20139.","journal-title":"Eur J Endocrinol"},{"key":"9386_CR73","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/imammb\/dqt005","volume":"31","author":"B Pandiyan","year":"2014","unstructured":"Pandiyan B, Merrill SJ, Benvenga S. A patient-specific model of the negative-feedback control of the hypothalamus-pituitary-thyroid (HPT) axis in autoimmune (Hashimoto\u2019s) thyroiditis. Math Med Biol. 2014;31:226\u201358.","journal-title":"Math Med Biol"},{"key":"9386_CR74","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/brain\/120.7.1149","volume":"120","author":"N Silver","year":"1997","unstructured":"Silver N, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Brain. 1997;120:1149\u201361.","journal-title":"Brain"},{"key":"9386_CR75","doi-asserted-by":"publisher","unstructured":"Velez de Mendizabal N, Hutmacher MM, Troconiz IF, Goni J, Villoslada P, Bagnato F, et al. Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach. PLoS One. 2013;8. doi: 10.1371\/journal.pone.0073361 .","DOI":"10.1371\/journal.pone.0073361"},{"key":"9386_CR76","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s11538-014-9955-5","volume":"76","author":"SL Goede","year":"2014","unstructured":"Goede SL. Leow MK-SS, Smit JWA, Klein HH, Dietrich JW: hypothalamus-pituitary-thyroid feedback control: implications of mathematical modeling and consequences for thyrotropin (TSH) and free thyroxine (FT4) reference ranges. Bull Math Biol. 2014;76:1270\u201387.","journal-title":"Bull Math Biol"},{"key":"9386_CR77","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/cen.12060","volume":"78","author":"HF Nystr\u00f6m","year":"2013","unstructured":"Nystr\u00f6m HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005. Clin Endocrinol. 2013;78:768\u201376.","journal-title":"Clin Endocrinol"},{"key":"9386_CR78","unstructured":"Sarokin D: What is a mechanistic Model? [Internet] [cited 2016 Aug 9];Available from: http:\/\/smallbusiness.chron.com\/mechanistic-model-12706.html ."}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-016-9386-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11154-016-9386-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-016-9386-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T11:26:41Z","timestamp":1718796401000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11154-016-9386-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,16]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["9386"],"URL":"https:\/\/doi.org\/10.1007\/s11154-016-9386-8","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,16]]}}}